A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
Public ClinicalTrials.gov record NCT04931342. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Open-Label, Multicenter, Platform Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
Study identification
- NCT ID
- NCT04931342
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Enrollment
- 176 participants
Conditions and interventions
Conditions
Interventions
- Abemaciclib Drug
- Atezolizumab Drug
- Bevacizumab Drug
- Cobimetinib Drug
- Cyclophosphamide Drug
- Giredestrant Drug
- Inavolisib Drug
- Ipatasertib Drug
- Letrozole Drug
- Luteinizing Hormone-Releasing Hormone (LHRH) Agonists Drug
- Olaparib Drug
- Paclitaxel Drug
- Palbociclib Drug
- Trastuzumab Emtansine Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 6, 2021
- Primary completion
- Feb 27, 2028
- Completion
- May 29, 2028
- Last update posted
- Mar 9, 2026
2021 – 2028
United States locations
- U.S. sites
- 8
- U.S. states
- 8
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCSF Helen Diller Family CCC | San Francisco | California | 94158 | — |
| Washington University School of Medicine | St Louis | Missouri | 63108 | — |
| Levine Cancer Institute | Charlotte | North Carolina | 28204 | — |
| Ohio State University | Columbus | Ohio | 43210 | — |
| University of Oklahoma Health Sciences Center | Oklahoma City | Oklahoma | 73104 | — |
| Texas Oncology - Gulf Coast | The Woodlands | Texas | 77380 | — |
| Virginia Oncology Associates | Norfolk | Virginia | 23502 | — |
| University of Washington - Seattle Cancer Care Alliance | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 33 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04931342, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 9, 2026 · Synced Apr 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04931342 live on ClinicalTrials.gov.